MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers
(Thomson Reuters ONE) -
PHILADELPHIA and HOUSTON, United States and OXFORD, United Kingdom, Sept.
26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a
leader in T-cell therapy to treat cancer, and The University of Texas MD
Anderson Cancer Center announced today that they have entered into a multi-year
strategic alliance designed to expedite the development of novel adoptive T-cell
therapies for multiple types of cancer.
The alliance pairs MD Anderson's preclinical and clinical teams with
Adaptimmune's scientists and proprietary SPEAR® (Specific Peptide Enhanced
Affinity Receptor) T-cell technology platform, which enables Adaptimmune to
identify targets expressed on solid and hematologic cancers and to develop
affinity enhanced T-cell receptors (TCRs) with optimal potency and specificity
against them.
The teams will collaborate in a number of areas including preclinical and
clinical development of Adaptimmune's SPEAR T-cell therapies targeting MAGE-A10
and future clinical stage first and second generation SPEAR T-cell therapies
such as MAGE-A4 across a number of cancers, including bladder, lung, ovarian,
head and neck, melanoma, esophageal and gastric cancers. The alliance will also
drive research and development of other new SPEAR TCR therapies to targets in
other tumor types such as breast cancers and facilitate clinical study
participation by MD Anderson in other Adaptimmune trials. Access to MD
Anderson's tumor repository will guide further target selection and clinical
trial design, while its cancer immunology cores and expertise in performing
translational medicine studies may help optimize the efficacy and safety of
SPEAR T-cell therapies.
"At MD Anderson, we are focused on providing the best possible care for cancer
patients, including implementing important new technologies and treatment
modalities," said Elizabeth Mittendorf, M.D., Ph.D., associate professor of
Breast Surgical Oncology.
David Hong, M.D., associate professor of Investigational Cancer Therapeutics at
MD Anderson added, "It is our hope this alliance will allow us to address
numerous solid tumors and augment the patient's immune system, directing it
against tumors based on their specific molecular makeup."
"We believe that this strategic alliance will provide a strong partnership for
the development of multiple new first and subsequent generation SPEAR T-cell
therapies against many intractable solid tumors in our near-term clinical
programs," commented Rafael Amado, Adaptimmune's chief medical officer. "It
will also generate invaluable data from patient samples that will help us
understand these therapies and design the next generation of studies. We are
very proud to form this alliance with the outstanding team of cancer
immunologists at MD Anderson, and are confident that together we can move these
novel immunotherapeutic candidates forward for patients who are fighting a
variety of cancers."
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the
world's most respected centers focused on cancer patient care, research,
education and prevention. The institution's sole mission is to end cancer for
patients and their families around the world. MD Anderson is one of only 45
comprehensive cancer centers designated by the National Cancer Institute (NCI).
MD Anderson is ranked No.1 for cancer care in U.S. News & World Report's "Best
Hospitals" survey. It has ranked as one of the nation's top two hospitals since
the survey began in 1990, and has ranked first for nine of the past 10 years. MD
Anderson receives a cancer center support grant from the NCI of the National
Institutes of Health (P30 CA016672).
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel
cancer immunotherapy products based on its SPEAR® (Specific Peptide Enhanced
Affinity Receptor) T-cell platform. Established in 2008, the company aims to
utilize the body's own machinery - the T-cell - to target and destroy cancer
cells by using engineered, increased affinity TCRs as a means of strengthening
natural patient T-cell responses. Adaptimmune's lead program is a SPEAR T-cell
therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has
demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid
tumors and in hematologic cancer types, including synovial sarcoma and multiple
myeloma. Adaptimmune has a strategic collaboration and licensing agreement with
GlaxoSmithKline for the development and commercialization of the NY-ESO TCR
program. In addition, Adaptimmune has a number of proprietary programs. These
include SPEAR T-cell therapies targeting the MAGE-A10 and AFP cancer antigens,
which both have open INDs, and a further SPEAR T-cell therapy targeting the
MAGE-A4 cancer antigen that is in pre-clinical phase with IND acceptance
targeted for 2017. The company has identified over 30 intracellular target
peptides preferentially expressed in cancer cells and is currently progressing
12 through unpartnered research programs. Adaptimmune has over 250 employees and
is located in Oxfordshire, U.K. and Philadelphia, USA. For more
information: http://www.adaptimmune.com
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking
statements involve certain risks and uncertainties. Such risks and uncertainties
could cause our actual results to differ materially from those indicated by such
forward-looking statements, and include, without limitation: the success, cost
and timing of our product development activities and clinical trials and our
ability to successfully advance our TCR therapeutic candidates through the
regulatory and commercialization processes. For a further description of the
risks and uncertainties that could cause our actual results to differ materially
from those expressed in these forward-looking statements, as well as risks
relating to our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC) on August
8, 2016, and our other SEC filings. The forward-looking statements contained in
this press release speak only as of the date the statements were made and we do
not undertake any obligation to update such forward-looking statements to
reflect subsequent events or circumstances.
Adaptimmune Contacts
Will Roberts
Vice President, Investor Relations
T: (215) 825-9306
E: will.roberts(at)adaptimmune.com
Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
E: margaret.henry(at)adaptimmune.com
MD Anderson Contact:
Ron Gilmore
Rlgilmore1(at)mdanderson.org
Phone: 713-745-1898
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Adaptimmune Therapeutics plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 26.09.2016 - 13:30 Uhr
Sprache: Deutsch
News-ID 496982
Anzahl Zeichen: 7925
contact information:
Town:
Philadelphia
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers"
steht unter der journalistisch-redaktionellen Verantwortung von
Adaptimmune Therapeutics plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
